FDA finds safety concerns with J&J attention-deficit drug

Share this article:
The FDA has identified a set of possible safety concerns with Johnson & Johnson's attention-deficit disorder drug Concerta, the agency said in a statement posted on its Web site yesterday.
A panel of FDA advisors is scheduled to discuss post-marketing reports of hallucinations, psychotic behavior, suicidal thoughts and heart complications such as high blood pressure at a meeting in Rockville, Md. tomorrow.
Concerta is a once-daily form of Novartis' Ritalin and the most prescribed drug for attention deficit hyperactivity disorder (ADHD), according to a Johnson & Johnson Web site.
Last year, the FDA gave doctors warnings about sudden cardiovascular death linked to another ADHD drug, Shire's Adderall. Canadian health officials in February ordered Adderall to be withdrawn from the market after it was linked to at least 20 deaths.
A Johnson & Johnson spokeswoman said in published reports that the company would not discuss the FDA's statement ahead of Thursday's meeting.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union